XRCC3 and ovarian carcinoma: Meta-analysis of the total studies showed that there was no association between XRCC3 Thr241Met polymorphism and risk of ovarian cancer under all five genetic models in overall population (T vs. C: OR = 0.99, 95 % CI = 0.96–1.03, P = 0.752; TT vs. CC: OR = 1.00, 95 % CI = 0.91–1.10, P = 0.943; TC vs. TT: OR = 0.97, 95 % CI = 0.92–1.04, P = 0.396, Fig. 1; TT vs. TC/CC: OR = 1.00, 95 % CI = 0.91–1.12, P = 0.874; TT/TC vs. CC: OR = 0.98, 95 % CI = 0.94–1.03, P = 0.486).